Evidence map›Paper›PMID 42876677›Full record

ArticleFrontiers in cellular and infection microbiology2026

Immunogenicity and protective efficacy of recombinant BCG expressing a multi-epitope vaccine against mycobacterium tuberculosis.

Xuan-Ji Zhang, Jia-Rui Luo, Ting-Ting Tian, Juan Shi, Zheng-Long Chai, Chuang Li, Si-Yu Zhang, Tao Qu, Feng-Bo Zhang, Yue-Jie Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xuan-Ji Zhang *Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Jia-Rui Luo *Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Ting-Ting TianDepartment of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Juan ShiDepartment of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Zheng-Long ChaiDepartment of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Chuang LiDepartment of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Si-Yu ZhangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Tao QuDepartment of Clinical Laboratory, The Second People's Hospital of Kashgar Prefecture, Kashgar, Xinjiang, China.
Feng-Bo ZhangDepartment of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Yue-Jie ZhuReproductive Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: tMEV was constructed from dominant T- and B-cell epitopes derived from Mtb ESAT-6, PE35, PPE38, and PE4 proteins, fused with an adjuvant. Its vaccine candidacy was assessed via physicochemical and solubility profiling, secondary and tertiary structure modeling, TLR-4 molecular docking, molecular dynamics simulation, and immune simulation. The tMEV coding sequence was cloned into pMV361 and transformed into BCG to generate recombinant BCG (rBCG-tMEV). Immunogenicity, antigenicity, and protective efficacy were evaluated in mouse immunization and Mtb challenge models. Results: tMEV exhibited favorable vaccine-like properties Discussion: These findings demonstrate that tMEV and rBCG-tMEV possess robust immunogenicity and protective potential against Mtb, representing promising novel TB vaccine candidates and providing a rationale for future vaccine development and optimization.

Indexed as

BCG VaccineEpitopesEpitopes, T-LymphocyteImmunogenicity, VaccineMycobacterium tuberculosisTuberculosisTuberculosis VaccinesAnimalsAntibodies, BacterialAntigens, BacterialCytokinesDisease Models, AnimalEpitopes, B-LymphocyteFemaleImmunoinformaticsInterferon-gammaAntibodies, BacterialAntigens, BacterialBCG VaccineCytokinesEpitopesEpitopes, B-LymphocyteEpitopes, T-LymphocyteInterferon-gammaProtein Subunit VaccinesTuberculosis VaccinesVaccines, SyntheticESAT-6.1multi-epitope vaccinerecombinant BCGshuttle plasmidT7SStuberculosis (TB)

Identifiers

PMID42876677
PMCPMC13661456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.